While BCL2 family proteins are thought to be partially responsible for the ability of senescent cells to resist apoptosis, and BCL2/BCL2L1/BCL2L2 inhibitors are effective senolytic drugs (e.g. ABT-263)68, there is a concern that BCL2 inhibitors may also trigger toxic effects, such as thrombocytopenia and neutropenia69. This evidence concerns the gene BCL2L1 and Thrombocytopenia.